Argenica Therapeutics Ltd (AGN) - Cash Flow Conversion Efficiency

Latest as of December 2025: -1.602x

Based on the latest financial reports, Argenica Therapeutics Ltd (AGN) has a cash flow conversion efficiency ratio of -1.602x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-5.51 Million ≈ $-3.90 Million USD) by net assets (AU$3.44 Million ≈ $2.44 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See AGN net asset quality index to measure how much of total assets are equity-financed.

Argenica Therapeutics Ltd - Cash Flow Conversion Efficiency Trend (2019–2024)

This chart illustrates how Argenica Therapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check AGN cash flow quality score to evaluate the quality of earnings relative to operating cash generation.

Argenica Therapeutics Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Argenica Therapeutics Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Energys Group Limited Ordinary Shares NASDAQ:ENGS	N/A
Concord Medical Services Holdings NYSE:CCM	0.009x
ES Australia Israel Holdings Ltd TA:AUIS	-0.084x
EcoBio Holdings Co. Ltd KQ:038870	0.027x
Samyoung S&C Co. Ltd. KQ:361670	-0.051x
CNPLUS Co. Ltd. KQ:115530	0.851x
LQwD FinTech Corp V:LQWD	-0.022x
CMX GOLD+SILVER CORP. F:6GS	-4.784x

Annual Cash Flow Conversion Efficiency for Argenica Therapeutics Ltd (2019–2024)

The table below shows the annual cash flow conversion efficiency of Argenica Therapeutics Ltd from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see Argenica Therapeutics Ltd (AGN) market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	AU$7.24 Million ≈ $5.12 Million	AU$-5.70 Million ≈ $-4.04 Million	-0.788x	-117.29%
2023-12-31	AU$13.95 Million ≈ $9.87 Million	AU$-5.06 Million ≈ $-3.58 Million	-0.363x	+15.74%
2022-12-31	AU$7.67 Million ≈ $5.42 Million	AU$-3.30 Million ≈ $-2.34 Million	-0.430x	-6.38%
2021-12-31	AU$8.31 Million ≈ $5.88 Million	AU$-3.36 Million ≈ $-2.38 Million	-0.405x	-164.77%
2020-12-31	AU$6.85 Million ≈ $4.84 Million	AU$-1.05 Million ≈ $-740.40K	-0.153x	+95.22%
2019-12-31	AU$18.40K ≈ $13.02K	AU$-58.82K ≈ $-41.62K	-3.197x	--

About Argenica Therapeutics Ltd

AU:AGN Australia Biotechnology

Market Cap

$13.63 Million

AU$19.27 Million AUD

Market Cap Rank

#26235 Global

#1188 in Australia

Share Price

AU$0.15

Change (1 day)

-3.23%

52-Week Range

AU$0.09 - AU$0.73

All Time High

AU$0.99